19. Lysosomal storage disease Clinical trials / Disease details

Clinical trials : 854 / Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02663024 (ClinicalTrials.gov)	December 2016	17/1/2016	Study of Idursulfase-beta (GC1111) in Hunter Syndrome	Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Idursulfase-beta (GC1111) in Hunter Syndrome (Mucopolysaccharidosis II) Patients	Mucopolysaccharidosis II	Biological: idursulfase beta;Biological: idursulfase	Green Cross Corporation	NULL	Not yet recruiting	5 Years	35 Years	Male	20	Phase 2	NULL
2	JPRN-JMA-IIA00350	29/07/2016	04/06/2018	Phase I/II clinical trial of idursulfase beta for mucopolysaccharidosis type II	Phase I/II clinical trial of idursulfase beta for mucopolysaccharidosis type II	Patients at the age between 6 months and 15 years with severe type mucopolysaccharidosis type II intravenously administered isursulfase at least for 24 weeks	Intervention type:DRUG. Intervention1:BHP001, Dose form:INJECTION, Route of administration:OTHER.	Torayuki Okuyama	Haruo Shintaku	Completed	>=6 MONTHS	<15 YEARS	Male	6	Phase 1-2	Japan
3	NCT01645189 (ClinicalTrials.gov)	July 2012	16/7/2012	Safety and Efficacy of Hunterase	To Evaluate the Safety and Efficacy of Hunterase(Idursulfase-beta) in Hunter Syndrome Patients < 6 Years of Age Receiving Idursulfase Enzyme Replacement Therapy	Hunter Syndrome	Biological: Hunterase	Green Cross Corporation	NULL	Completed	N/A	5 Years	Male	6	Phase 3	Korea, Republic of